Comparative Pharmacology
Head-to-head clinical analysis: BALSALAZIDE DISODIUM versus MELAMISA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BALSALAZIDE DISODIUM versus MELAMISA.
BALSALAZIDE DISODIUM vs MELAMISA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Prodrug that delivers mesalamine (5-aminosalicylic acid) to the colon; mesalamine inhibits cyclooxygenase and lipoxygenase pathways, reducing prostaglandin and leukotriene synthesis, and scavenges reactive oxygen species, thereby decreasing colonic inflammation.
Meloxicam selectively inhibits cyclooxygenase-2 (COX-2), reducing the synthesis of prostaglandins involved in inflammation, pain, and fever, while sparing COX-1 activity at therapeutic doses.
2.25 g (three 750 mg capsules) orally three times daily
100 mg orally twice daily for 5 days; take with food.
None Documented
None Documented
Balsalazide itself has a terminal elimination half-life of approximately 0.5–1 hour; the active moiety mesalamine has a terminal half-life of 5–10 hours, which may be prolonged in renal impairment.
Terminal elimination half-life is 6.5–9.8 hours in adults with normal renal function; prolonged to >24 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Primarily excreted in feces via biliary elimination (approximately 90%) following conversion to mesalamine; renal excretion accounts for less than 10% of the dose as mesalamine and its metabolites.
Renal (approximately 50% as unchanged drug and metabolites), biliary/fecal (approximately 30%), with minor pulmonary elimination. Total clearance is about 1.2 mL/min/kg.
Category C
Category C
Aminosalicylate
Aminosalicylate